New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
08:32 EDTBTXBioTime unit announces $14.3M strategic partnership award from CIRM
Asterias Biotherapeutics, a subsidiary of BioTime, announced that it has been awarded a $14.3M Strategic Partnership III grant entitled “A Phase 1/2a Dose Escalation Study of AST-OPC1 in Patients with Cervical Sensorimotor Complete Cervical Spinal Cord Injury” from the California Institute for Regenerative Medicine. The award provides funding for Asterias to reinitiate clinical development of AST-OPC1 in subjects with spinal cord injury and to expand clinical testing of escalating doses in the target population intended for future pivotal trials.
News For BTX From The Last 14 Days
Check below for free stories on BTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
09:01 EDTBTXBioTime announces collaboration with University of Wisconsin, Louvain University
Subscribe for More Information
August 27, 2014
09:02 EDTBTXBioTime unit receives FDA clearance to initiate Phase 1/2a trial of AST-OPC1
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use